Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Current Assets (2016 - 2025)

Avalo Therapeutics filings provide 12 years of Current Assets readings, the most recent being $105.3 million for Q4 2025.

  • On a quarterly basis, Current Assets fell 24.19% to $105.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $105.3 million, a 24.19% decrease, with the full-year FY2025 number at $105.3 million, down 24.19% from a year prior.
  • Current Assets hit $105.3 million in Q4 2025 for Avalo Therapeutics, down from $113.8 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $138.9 million in Q4 2024 to a low of $7.5 million in Q2 2023.
  • Median Current Assets over the past 5 years was $54.6 million (2021), compared with a mean of $63.4 million.
  • Biggest five-year swings in Current Assets: crashed 74.74% in 2022 and later soared 1554.44% in 2024.
  • Avalo Therapeutics' Current Assets stood at $61.8 million in 2021, then crashed by 73.46% to $16.4 million in 2022, then plummeted by 48.86% to $8.4 million in 2023, then soared by 1554.44% to $138.9 million in 2024, then decreased by 24.19% to $105.3 million in 2025.
  • The last three reported values for Current Assets were $105.3 million (Q4 2025), $113.8 million (Q3 2025), and $115.2 million (Q2 2025) per Business Quant data.